Trial Profile
A 12-week , Randomized, Phase 2, Double-blind, Parallel-group Study Of Two Dose Levels Of Pf-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-optimally Controlled Symptoms Of Schizophrenia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Mardepodect (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Pfizer
- 06 Oct 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 17 Jun 2014 Planned End Date changed from 1 Aug 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov record.
- 01 Oct 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.